AtriCure ATRC announces its next round of earnings Monday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.
Earnings and Revenue
Sell-side analysts are expecting AtriCure's loss per share to be near 21 cents on sales of $45.36 million.
In the same quarter last year, AtriCure reported a loss per share of 27 cents on sales of $41.15 million. Analysts estimate would represent a 22.22 percent decrease in the company's earnings. Sales would be up 10.21 percent from the same quarter last year.
Here's how the company's reported EPS has compared to analyst estimates in the past:
| Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
| EPS Estimate | -0.24 | -0.26 | -0.35 | -0.31 |
| EPS Actual | -0.22 | -0.21 | -0.32 | -0.27 |
Stock Performance
Over the last 52-week period, shares are up 3.75 percent. Given that these returns are generally positive, long-term shareholders are probably content going into this earnings release.
Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. The popular rating by analysts on AtriCure stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Conference Call
AtriCure is scheduled to hold a conference call at 4:30 p.m. ET and it can be accessed here: http://ir.atricure.com/phoenix.zhtml?c=189981&p=irol-irhome
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
